Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
Open Access
- 1 April 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 58 (4) , 220-225
- https://doi.org/10.1136/ard.58.4.220
Abstract
OBJECTIVES To investigate the potential clinical benefit of a combination therapy. METHODS 205 patients fulfilling the ACR criteria for rheumatoid arthritis (RA), not treated with disease modifying anti-rheumatoid drugs previously, with an early (⩽1 year duration), active (Disease Activity Score (DAS) > 3.0), rheumatoid factor and/or HLA DR 1/4 positive disease were randomised between sulphasalazine (SASP) 2000 (maximum 3000) mg daily (n = 68), or methotrexate (MTX) 7.5 (maximum 15) mg weekly (n = 69) or the combination (SASP + MTX) of both (n = 68). RESULTS The mean changes in the DAS during the one year follow up of the study was −1.15, −0.87, −1.26 in the SASP, MTX, and SASP + MTX group respectively (p = 0.019). However, there was no statistically significant difference in terms of either EULAR good responders 34%, 38%, 38% or ACR criteria responders 59%, 59%, 65% in the SASP, MTX, and SASP + MTX group respectively. Radiological progression evaluated by the modified Sharp score was very modest in the three groups: mean changes in erosion score: +2.4, +2.4, +1.9, in narrowing score: +2.3, +2.1, +1.6 and in total damage score: +4.6, +4.5, +3.5, in the SASP, MTX, and SASP + MTX groups respectively. Adverse events occurred more frequently in the SASP + MTX group 91% versus 75% in the SASP and MTX group (p = 0.025). Nausea was the most frequent side effect: 32%, 23%, 49% in the SASP, MTX, and SASP + MTX groups respectively (p = 0.007). CONCLUSION This study suggests that an early initiation therapy of disease modifying drug seems to be of benefit. However, this study was unable to demonstrate a clinically relevant superiority of the combination therapy although several outcomes were in favour of this observation. The tolerability of the three treatment modalities seems acceptable.Keywords
This publication has 34 references indexed in Scilit:
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- PROGNOSTIC FACTORS IN RHEUMATOID ARTHRITIS. COMPARATIVE STUDY OF TWO SUBSETS OF PATIENTS ACCORDING TO SEVERITY OF ARTICULAR DAMAGERheumatology, 1995
- COMBINATION OF METHOTREXATE AND SULPHASALAZINE VS METHOTREXATE ALONE: A RANDOMIZED OPEN CLINICAL TRIAL IN RHEUMATOID ARTHRITIS PATIENTS RESISTANT TO SULPHASALAZINE THERAPYRheumatology, 1994
- The efficacy and toxicity of combination therapy in rheumatoid arthritis. a meta‐analysisArthritis & Rheumatism, 1994
- Combination Therapy with Methotrexate and Chloroquine in Rheumatoid Arthritis:A Multicenter Randomized Placebo-controlled TrialScandinavian Journal of Rheumatology, 1994
- Radiologic assessment as an outcome measure in rheumatoid arthritisArthritis & Rheumatism, 1989
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980
- Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalitiesArthritis & Rheumatism, 1971